Aging and “medical inflation” reignite the debate over caps on major medical insurance premiums
Heavier use of services by older adults and persistently rising hospital costs are pushing premiums higher and complicating the idea of limiting increases by law.
The rising cost of major medical insurance has moved back to the center of Mexico’s public debate amid proposals in Congress aimed at putting a brake on premium increases, particularly for older adults. The latest proposal would cap annual adjustments for people 60 and older at inflation plus five percentage points, at a time when policyholders report hikes of 40% or even more at certain renewals.
The debate hits a sensitive issue for household finances: the combination of growing medical spending, higher demand for services, and the country’s demographic transition. While lawmakers’ intent is to protect insured individuals from sudden jumps, the industry argues that the price of a policy is not arbitrary, but rather the result of actuarial calculations that reflect how often insurance is used and how much it costs to cover each claim.
According to industry figures, Mexico ended 2024 with around 13.9 million major medical policies, of which 4.3 million are individual plans. Within that segment, roughly 699,000 insureds age 60 and older (16% of the total) accounted for as much as 40% of claims paid. In addition, their utilization rate reached 21.3%—more than double the overall average (9.3%)—a figure that illustrates why an aging risk pool puts pressure on the system’s cost.
Pedro Pacheco, president of the Mexican Association of Insurance Institutions (AMIS), has said the increase is driven by structural factors: medical inflation—typically above headline inflation—greater use of technology, and longer treatments associated with chronic diseases. Under that logic, limiting increases without addressing underlying cost growth could undermine the product’s technical viability or lead to adjustments through other channels, such as changes to deductibles, coinsurance, or covered benefits.
From a macroeconomic standpoint, the discussion is unfolding in a country where healthcare spending falls heavily on families’ out-of-pocket budgets, and where access to private services serves, for part of the population, as a release valve amid pressure and wait times in the public system. Even so, health insurance penetration remains limited compared with advanced economies, which heightens the tension between expanding coverage and keeping prices affordable.
Premium caps: immediate relief vs. long-term risks
The idea of setting a ceiling on annualized increases seeks to give older adults more budget certainty—a group particularly vulnerable to premium “jumps” at renewal. But in insurance, price is closely tied to risk: if claims rise faster than the allowed cap, the insurer faces a gap it must absorb, offset with other books of business, or address by changing contract terms. At the extreme, price controls can lead to tighter supply for older ages, greater market segmentation, or products with more limited protection. In an economy with rapidly accelerating aging—and with a higher prevalence of chronic conditions like diabetes and hypertension—public policy design becomes critical to keep the cure from reducing options or indirectly making coverage more expensive.
An additional component of the legislative proposal is the creation of an amortization fund financed from the early stages of coverage, with the goal of spreading risk costs over the insured’s lifetime and softening steep increases at older ages. The approach resembles a savings or reserve scheme—similar in logic to retirement planning: it requires long-term discipline, clear rules on portability, and transparency on fees and returns, along with oversight to prevent it from becoming an added cost with no tangible benefit for the user.
At the same time, the policyholder experience remains a relevant issue. Data from the financial consumer protection authority show that, while the volume of complaints in major medical insurance is low relative to insured risks, the share resolved in the user’s favor remains limited and varies widely by company. Challenges also persist around response times and clarity of terms—factors that shape the perceived value of insurance beyond the annual price.
From the industry’s perspective, the challenge is significant: insurers report substantial claim payments across all lines, underscoring their role as a mechanism for protecting household wealth. In major medical, maintaining the balance among premiums, claims, and solvency becomes more complex as demand for highly specialized services grows and the costs of hospital inputs, medications, and procedures climb—a trend that often follows its own trajectory, frequently running above headline inflation.
Looking ahead, the legislative debate points to a broader dilemma that goes beyond the sector: how to finance healthcare in an aging society, with rising medical costs and still-limited insurance coverage. The discussion of caps may ease individual cases in the short run, but its effectiveness will depend on complementary measures: product innovation, prevention and chronic-disease management programs, greater competition and market transparency, and regulatory coordination that raises quality of care and reduces disputes.
In sum, the premium increases reflect real pressure from costs and utilization—especially among older adults—and any legal cap will have to balance consumer protection with technical sustainability so the problem isn’t shifted to thinner coverage or fewer policies available.
